A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Zhao, Shilin, Wang, Jing, Sheng, Quanhu, Liu, Qi, Shyr, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Resource Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189237/
https://www.ncbi.nlm.nih.gov/pubmed/34903605
http://dx.doi.org/10.1158/0008-5472.CAN-21-2335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189237/
https://www.ncbi.nlm.nih.gov/pubmed/34903605
http://dx.doi.org/10.1158/0008-5472.CAN-21-2335

Ejemplares similares